TRENDSPOTTER: Genomic Sector Deserves Laissez Faire, Not Potential Patent Threats, in Light of Bioterror | GenomeWeb

In the war against bioterror, genomic companies are becoming more noticeable. Consider: Maxygen has received grants from DARPA for its MolecularBreeding technologies, which promise rapidly to deliver antigens for immunization. The technology also has been designed to generate new vaccines with a broad spectrum of activity against multiple strains of several different pathogens, and deliver aerosol-based preventative and therapeutic agents.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.